1. P37 Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer's disease. Issue 8 (August 2019) Authors: Boada, M.; Ristic, S.; Pross, N.; Abi-Saab, D.; Bullain, S.; Andjelkovic, M.; Peters, O.; Delmar, P.; Hofmann, C.; Searle, A.; Baudler, M.; Fontoura, P.; Doody, R. Journal: Clinical neurophysiology Issue: Volume 130:Issue 8(2019:Aug.) Page Start: e163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P33 Thirty-six-month amyloid PET results show continued reduction in amyloid burden with gantenerumab. Issue 4 (April 2020) Authors: Klein, G.; Duning, T.; Delmar, P.; Kerchner, G.A.; Hofmann, C.; Abi-Saab, D.; Ristic, S.; Davis, A.; Voyle, N.; Baudler, M.; Fontoura, P.; Doody, R. Journal: Clinical neurophysiology Issue: Volume 131:Issue 4(2020:Apr.) Page Start: e195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗